Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516033 | 0.84 | TAAR1 (0.73) | TAAR1SLC6A2SIGMAR1 | |
| SCHEMBL5516493 | 0.83 | IDO1 (0.47) | LTA4HTAAR1CASRIDO1AGXT | |
| SCHEMBL9583292 | 0.83 | TAAR1 (0.52) | LTA4HTAAR1CASRIDO1AGXT | |
| SCHEMBL8976499 | 0.82 | LTA4H (0.52) | LTA4HTAAR1SLC6A2SIGMAR1MMP1 | |
| SCHEMBL5305755 | 0.82 | LTA4H (0.52) | LTA4HTAAR1SLC6A2SIGMAR1MMP1 | |
| Ammonia Solution, Strong SCHEMBL2477835 | 0.82 | SLC6A2 (0.70) | TAAR1SLC6A2SIGMAR1 | |
| SCHEMBL17964411 | 0.81 | LTA4H (0.55) | LTA4HTAAR1SLC6A2SIGMAR1HTT | |
| SCHEMBL183751 | 0.80 | SLC6A2 (0.57) | LTA4HTAAR1SLC6A2IDO1AGXT | |
| SCHEMBL17964410 | 0.80 | LTA4H (0.53) | LTA4HTAAR1SLC6A2SIGMAR1HTT | |
| SCHEMBL28222289 | 0.79 | LTA4H (0.62) | LTA4HSIGMAR1MMP1MMP13HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2195285-B1 | ACETAMIDE STEREOISOMER | SUNOVION PHARMACEUTICALS INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9499476-B2 | Acetamide stereoisomer | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150225334-A1 | ACETAMIDE STEREOISOMER | SUNOVION PHARMACEUTICALS INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9040588-B2 | Acetamide stereoisomer | SUNOVION PHARMACEUTICALS INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140135300-A1 | Acetamide Stereoisomer | SUNOVION PHARMACEUTICALS INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8664441-B2 | Acetamide stereoisomer | SUNOVION PHARMACEUTICALS INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130296607-A1 | Acetamide Stereoisomer | SUNOVION PHARMACEUTICALS, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501994-B2 | Acetamide stereoisomer | SUNOVION PHARMACEUTICALS INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2190813-B1 | CARBAMATE STEREOISOMER | SEPRACOR INC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8173829-B2 | Carbamate stereoisomer | SUNOVION PHARMACEUTICALS INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100215589-A1 | Carbamate Stereoisomer | SEPRACOR INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-7718822-B2 | Carbamate Stereoisomer | SEPRACOR INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090060917-A1 | Carbamate Stereoisomer | SEPRACOR INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060922-A1 | Acetamide Stereoisomer | SEPRACOR INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135300-A1 | Acetamide Stereoisomer | ADRB2, ADRA2A, ADRB1 | LTA4H 116/4885TAAR1 160/4885SLC6A2 1256/4885 |
| US-20150225334-A1 | ACETAMIDE STEREOISOMER | ADRB2, ADRA2A, ADRB1 | LTA4H 116/4885TAAR1 160/4885SLC6A2 1256/4885 |
| US-20090060917-A1 | Carbamate Stereoisomer | ADRB2, CHRM3, CHRM2 | LTA4H 355/4885TAAR1 641/4885SLC6A2 1600/4885 |
| US-20100215589-A1 | Carbamate Stereoisomer | ADRB2, CHRM3, CHRM2 | LTA4H 355/4885TAAR1 641/4885SLC6A2 1600/4885 |
| US-20090060922-A1 | Acetamide Stereoisomer | ADRB2, ADRA2A, ADRB1 | LTA4H 114/4885TAAR1 161/4885SLC6A2 1066/4885 |
| US-20130296607-A1 | Acetamide Stereoisomer | ADRB2, ADRA2A, ADRB1 | LTA4H 116/4885TAAR1 160/4885SLC6A2 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.